Literature DB >> 15641062

Presentation and analysis of data on radiographic outcome in clinical trials: experience from the TEMPO study.

Désirée van der Heijde1, Robert Landewé, Lars Klareskog, Vicente Rodríguez-Valverde, Lucas Settas, Ronald Pedersen, Saeed Fatenejad.   

Abstract

OBJECTIVE: To evaluate different methods of presentation and analysis of radiographic data in a rheumatoid arthritis (RA) randomized controlled trial.
METHODS: A double-blind randomized controlled trial including 682 patients with active RA who were treated with methotrexate, etanercept, or a combination of the 2 drugs was used for this study. Probability plots of the change from baseline to year 1 were produced to visualize progression, and were compared with usual descriptive statistics. The primary analysis of the trial (based on annualized actual mean change from baseline in total Sharp score at 1 year, using linear imputation) was challenged using various ways of handling missing information with alternative imputation methods, and by various statistical analyses including analysis of covariance (ANCOVA) and mixed model analysis on both raw and log-transformed data.
RESULTS: Probability plots provided detailed insight into the differentiated treatment effects between the 3 arms of this study. As adjuncts to formal hypothesis testing, these plots were more useful for presenting data than were summary descriptive statistics or use of preset cutoff points to define lack of progression. Additional analyses presented here support the results obtained with the per-protocol analysis that showed an advantage of the combination treatment compared with the monotherapy arms and for etanercept versus methotrexate alone. Various ways of handling missing information confirmed the robustness of the results. In addition, both ANCOVA and mixed model analyses on raw and on log-transformed data produced similar results.
CONCLUSION: We suggest a panel of alternative analysis methods and alternative ways of handling missing information to verify that the radiographic results reported in an randomized controlled trial are not influenced by technical factors, such as interpolation, handling of missing data, and choice of statistical tests.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15641062     DOI: 10.1002/art.20775

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  17 in total

Review 1.  Presentation and analysis of radiographic data in clinical trials and observational studies.

Authors:  R Landewé; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

Review 2.  The role of secukinumab in the treatment of psoriatic arthritis and ankylosing spondylitis.

Authors:  Leticia Garcia-Montoya; Helena Marzo-Ortega
Journal:  Ther Adv Musculoskelet Dis       Date:  2018-09-06       Impact factor: 5.346

3.  Performance of computer-based analysis using temporal subtraction to assess joint space narrowing progression in rheumatoid patients.

Authors:  Shota Ichikawa; Tamotsu Kamishima; Kenneth Sutherland; Takanobu Okubo; Kou Katayama
Journal:  Rheumatol Int       Date:  2015-08-23       Impact factor: 2.631

4.  [Therapeutic strategies in rheumatoid arthritis].

Authors:  H Bastian; E Feist; G-R Burmester
Journal:  Internist (Berl)       Date:  2011-06       Impact factor: 0.743

5.  Impact of sex, age, body mass index and handedness on finger joint space width in patients with prolonged rheumatoid arthritis using computer-aided joint space analysis.

Authors:  Alexander Pfeil; Andreas Hansch; Gabriele Lehmann; Thorsten Eidner; Max L Schäfer; Peter Oelzner; Diane M Renz; Gunter Wolf; Gert Hein; Werner A Kaiser; Joachim Böttcher
Journal:  Rheumatol Int       Date:  2008-10-25       Impact factor: 2.631

6.  Discontinuation of etanercept in patients with rheumatoid arthritis who were in clinical remission.

Authors:  Tomoya Miyamura; Koshiro Sonomoto; Masataka Nakamura; Yoshiro Horai; Soichiro Takahama; Hitoshi Ando; Rumi Minami; Masahiro Yamamoto; Eiichi Suematsu
Journal:  Clin Rheumatol       Date:  2009-09-10       Impact factor: 2.980

7.  Adalimumab response in patients with early versus established rheumatoid arthritis: DE019 randomized controlled trial subanalysis.

Authors:  Shahin Jamal; Kaushik Patra; Edward C Keystone
Journal:  Clin Rheumatol       Date:  2008-12-09       Impact factor: 2.980

8.  Combination therapy for rheumatoid arthritis in the era of biologicals.

Authors:  Allan Gibofsky
Journal:  HSS J       Date:  2006-02

9.  Treating rheumatoid arthritis to target: recommendations of an international task force.

Authors:  Josef S Smolen; Daniel Aletaha; Johannes W J Bijlsma; Ferdinand C Breedveld; Dimitrios Boumpas; Gerd Burmester; Bernard Combe; Maurizio Cutolo; Maarten de Wit; Maxime Dougados; Paul Emery; Alan Gibofsky; Juan Jesus Gomez-Reino; Boulos Haraoui; Joachim Kalden; Edward C Keystone; Tore K Kvien; Iain McInnes; Emilio Martin-Mola; Carlomaurizio Montecucco; Monika Schoels; Désirée van der Heijde; Desirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2010-03-09       Impact factor: 19.103

10.  Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study.

Authors:  Jun Hashimoto; Patrick Garnero; Désirée van der Heijde; Nobuyuki Miyasaka; Kazuhiko Yamamoto; Shinichi Kawai; Tsutomu Takeuchi; Hideki Yoshikawa; Norihiro Nishimoto
Journal:  Mod Rheumatol       Date:  2010-06-24       Impact factor: 3.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.